Promega's OncoMate MSI system cleared by FDA

By LabPulse.com staff writers

July 30, 2021 -- Promega announced that its OncoMate microsatellite instability (MSI) Dx Analysis System has been cleared by the U.S. Food and Drug Administration (FDA) for use in labs in the U.S.

With the FDA clearance, the company said oncologists and pathologists in the U.S. can now access the IVD test that screens for Lynch syndrome in patients with colorectal cancer.

Promega SARS-CoV-2 antibody test gets CE Mark
Promega's SARS-CoV-2 antibody test, Lumit Dx SARS-CoV-2 Immunoassay, has received the CE Mark and is now available in Europe. The test is based on bioluminescence,...
Promega to further develop OncoMate MSI assay
Promega announced that it plans to further develop its OncoMate microsatellite instability (MSI) assay as a companion diagnostic test for Incyte's anti-PD-1...
Promega seeks EUA for COVID-19 antibody detection test
Promega applied to the U.S. Food and Drug Administration for an emergency use authorization (EUA) for its new serological antibody test for COVID-19,...
Promega microsatellite instability test gets CE Mark
Promega announced that its OncoMate microsatellite instability (MSI) diagnosis system for solid tumors has the CE Mark as a new in vitro diagnostic in...
Co-Diagnostics gets test kit manufacturing help from Promega
Molecular diagnostics company Co-Diagnostics has tapped Promega for additional manufacturing capacity for its COVID-19 test kits.

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 12:16:08 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current